The Ballast
Novartis (NVS) is the “Ballast” in Porter Stansberry’s Ignition Point pitch, the big, steady name meant to anchor the barbell while the smaller RNAi players do the speculative work. Porter Stansberry, the founder of Porter & Co. and the name behind the long-running Stansberry newsletter family, positions Novartis as the safe harbor of the group, and at a market cap near $269 billion it is easy to see why. This is one of the largest pharmaceutical companies on earth, trading around $142.71.
The pitch leans on a specific drug: pelacarsen, an antisense medicine licensed from Ionis that targets lipoprotein(a), the genetically determined cholesterol-like particle that statins and diet barely move. That is where the story gets uncomfortable, because the trial the promo celebrates has already reported results, and they do not say what the tease implies.
The Tease Versus Reality
The Ignition Point promotion describes Novartis as “the $150 billion Titan running the very first trial ever to prove lowering Lp(a) prevents cardiovascular events.” It is a big, clean claim, and it is central to the ballast thesis. If lowering Lp(a) actually prevented heart attacks and strokes, Novartis would own the answer to a question cardiology has chased for years.
The problem is that the trial already read out, and it did not prove that. The tease quietly runs about three weeks behind the news.
What Actually Happened
On September 4, 2026, Novartis reported the results of the pelacarsen outcomes trial, which enrolled more than 8,300 patients. The drug worked exactly as designed on its blood marker: it slashed Lp(a) levels sharply. But when researchers looked at the endpoint that actually matters, cardiovascular events such as heart attacks and strokes, pelacarsen did no better than a placebo.
That is the textbook definition of an endpoint failure. The biomarker fell, the clinical benefit did not follow, and the headline claim in the promo collapsed with it. We dig into why that keeps happening in our endpoint problem explainer.
Why the Biomarker Did Not Translate
The gap between Lp(a) and events is the core lesson here. Lp(a) is genetically determined, and people born with high levels do carry more cardiovascular risk over a lifetime. But lowering Lp(a) in adults, even by a lot, is not the same as never having had it in the first place. A lifetime of accumulated risk may not reverse just because the number drops for a few years, and that is exactly the possibility the trial result raises.
This is not a knock on Novartis as a company. It is a caution about the whole Lp(a) thesis that the Ignition Point pitch is built on. The biology is real, and we cover it in our lipoprotein(a) explainer, but the leap from a moving biomarker to a prevented heart attack is bigger than the promo lets on.
The Antisense Distinction
One detail worth understanding is that pelacarsen is not an RNAi drug. It is an antisense medicine, a related but distinct gene-silencing technology that Novartis licensed from Ionis. The two approaches share the same goal, turning off the gene that produces Lp(a), but they get there differently, and the distinction helps explain why the field has so many horses in the race.
Antisense uses a single modified strand to bind the messenger RNA and flag it for destruction. RNAi uses a two-stranded small interfering RNA and a cellular machine to do the silencing. Both can lower Lp(a) sharply, and both now face the same wall the pelacarsen trial exposed: the biomarker falls, but the question of whether that prevents events stays open.
Why does that matter for investors? Because the failure of the antisense drug does not automatically vindicate the RNAi drugs racing behind it, and the reverse is also true. They all lower the same number, so they all face the same unresolved question about whether lowering Lp(a) in adults actually saves lives. The distinction is technical. The conclusion is not: the Lp(a) thesis still rests on proof no one has produced yet.
The Read
None of this makes Novartis a bad business. It is a diversified pharmaceutical giant with a deep pipeline and steady cash flow, and it can absorb a failed trial without breaking stride. That is precisely what “ballast” is supposed to mean.
But the specific reason the promo gives for owning it, the first-ever proof that lowering Lp(a) prevents events, turned out not to exist. Investors buying the stock on that argument are buying a story the data already undercut. The license behind pelacarsen comes from Ionis, which we cover in our Ionis breakdown, and the honest read is that the safe name is safe, but the catalyst the pitch promised is gone. We walk through the specifics in our Silence Therapeutics Stock: Porter’s ‘Lightning Strike’ Pick piece.
Ready to see the research? Click here to access Porter Stansberry’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.